Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Capital Expenditures (2022 - 2025)

Entrada Therapeutics has reported Capital Expenditures over the past 4 years, most recently at -$207000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$207000.0 for Q4 2025, down 106.68% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 67.04% YoY), and the annual figure for FY2025 was $1.0 million, down 67.04%.
  • Capital Expenditures for Q4 2025 was -$207000.0 at Entrada Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for TRDA hit a ceiling of $3.1 million in Q2 2023 and a floor of -$2.9 million in Q3 2023.
  • Median Capital Expenditures over the past 4 years was $82500.0 (2023), compared with a mean of $455875.0.
  • Biggest five-year swings in Capital Expenditures: tumbled 355.28% in 2023 and later skyrocketed 3504.4% in 2024.
  • Entrada Therapeutics' Capital Expenditures stood at $2.9 million in 2022, then tumbled by 103.19% to -$91000.0 in 2023, then skyrocketed by 3504.4% to $3.1 million in 2024, then plummeted by 106.68% to -$207000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$207000.0 (Q4 2025), $1.2 million (Q3 2025), and -$108000.0 (Q2 2025) per Business Quant data.